One psilocybin dose eased chronic suicidal ideation for 12 weeks, in 20 patients

Chronic suicidal ideation that persists despite multiple antidepressant trials represents one of psychiatry's most difficult and highest-stakes treatment gaps. A trial published this month in the Journal of Clinical Psychiatry tests a single dose of psilocybin specifically in this population — people who had already failed at least two prior antidepressant treatments [s1].

The design

This open-label, single-arm study followed adults with chronic suicidal ideation and major depressive disorder, all of whom had experienced at least two prior antidepressant treatment failures, for 12 weeks after a single dose [s1]. Twenty participants received a single 25 mg dose of a proprietary synthetic psilocybin formulation, administered within a structured protocol including preparatory and post-dose integration psychotherapy [s1]. The primary outcome was change in the Modified Scale for Suicidal Ideation (MSSI) at three weeks; secondary outcomes included MSSI change at one and 12 weeks and Montgomery-Åsberg Depression Rating Scale (MADRS) changes at the same intervals [s1]. The trial ran between March 2022 and May 2025 [s1].

What it found

MSSI scores dropped significantly from baseline to the three-week primary endpoint (mean difference 13.95, 95% CI 8.63–19.27, p < .001; Cohen's d = 1.73, a very large effect size by conventional standards) [s1]. The improvement was both rapid and durable: significant reductions were already present at one week (mean difference 15.10, p < .001, d = 2.11) and remained substantial at 12 weeks (mean difference 13.00, p < .001, d = 1.46) [s1]. By the 12-week mark, 70% of participants (14 of 20) had MSSI scores of 2 or lower — a threshold the study treats as indicating near-resolution of suicidal ideation [s1]. Depression scores on the MADRS showed similarly large and significant reductions at every timepoint measured [s1]. No serious adverse events occurred [s1].

Why open-label results in this population still matter, despite the design limits

An open-label trial with no placebo arm and no blinding is a substantially weaker evidentiary design than a randomized, placebo-controlled trial — every participant in this study knew they were receiving psilocybin, which opens the door to expectation effects inflating the apparent benefit, particularly for a self-reported or clinician-assessed measure like suicidal ideation severity. That said, testing an intervention in a genuinely high-risk population — chronic suicidal ideation, multiple prior treatment failures — carries its own ethical and practical reasons for starting with an open-label safety and feasibility study before committing to a placebo-controlled design in this specific group, and the effect sizes reported here (d values above 1.4 at every timepoint) are large enough that they would be difficult, though not impossible, to fully explain by expectation effects alone.

What the effect-size numbers mean in plain terms

A Cohen's d of 1.73 at the primary endpoint is a very large effect by the standards typically used in psychiatric research, where effects in the 0.3–0.5 range are common for many interventions; effects above 0.8 are usually described as large. That size of effect, in an open-label study, is exactly the kind of striking result that most warrants a follow-up randomized, controlled trial to determine how much of it survives once expectation and non-specific treatment effects are accounted for — a point the study's own authors make directly.

What this doesn't establish

Twenty participants at a single site, with no control group, is a small and methodologically limited trial for as serious an outcome as suicidal ideation — a case where false hope from an inflated open-label effect size could carry real costs if not appropriately caveated. The study doesn't report whether any participants experienced worsening suicidal ideation or other significant psychological distress during the acute dosing period, information that would be important for fully assessing the intervention's risk profile in this specific, vulnerable population. The 90% male-or-mixed demographic composition isn't detailed in the available summary, limiting assessment of how findings might vary by other patient characteristics.

What the authors say is needed next

The study's authors explicitly frame these as "preliminary findings" that "support further evaluation in larger randomized controlled trials" [s1] — appropriately conservative language for an open-label pilot study, even given the large effect sizes reported.

What to watch

Whether a randomized, placebo-controlled trial in this same chronic suicidal ideation population confirms these findings at a scale that can better isolate a genuine drug effect. Psilocybin is not approved for suicidal ideation or depression; this article describes an early-stage investigational trial in a high-risk population and is not medical advice. Anyone experiencing suicidal thoughts should contact a mental health professional or a crisis line.

Sources

1. Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial — Journal of Clinical Psychiatry, 13 May 2026